TRIB1AL

1. TRIB1AL is associated with lifespan in silico.

   “lower liver-expressed TRIB1AL as being associated with reduced liver fat accumulation, lower plasma lipoprotein-lipid levels, decreased atherosclerotic cardiovascular disease risk, and increased human lifespan.”

   In silicoliver

   The long non-coding RNA TRIB1AL links metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk and human lifespan

   medRxiv·13 Jun 2025Preprint

1. TRIB1AL is associated with atherosclerotic cardiovascular disease in silico.

   “associated with reduced liver fat accumulation, lower plasma lipoprotein-lipid levels, decreased atherosclerotic cardiovascular disease risk, and increased human lifespan.”

   In silicoliver

   The long non-coding RNA TRIB1AL links metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk and human lifespan

   medRxiv·13 Jun 2025Preprint

More on Atherosclerotic cardiovascular disease

1. TRIB1AL is associated with liver fat accumulation in silico.

   “MR also identified lower liver-expressed TRIB1AL as being associated with reduced liver fat accumulation”

   In silicoliver

   The long non-coding RNA TRIB1AL links metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk and human lifespan

   medRxiv·13 Jun 2025Preprint

1. TRIB1AL raises the risk of metabolic dysfunction-associated steatotic liver disease in silico.

   “we found a strong and positive effect of the long non-coding RNA TRIB1AL on MASLD.”

   In silicoliver

   The long non-coding RNA TRIB1AL links metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk and human lifespan

   medRxiv·13 Jun 2025Preprint

More on Metabolic dysfunction-associated steatotic liver disease